C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 84 filers reported holding C4 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1 | -96.0% | 320 | -95.9% | 0.00% | – |
| Q1 2023 | $25 | -85.2% | 7,864 | -72.5% | 0.00% | – |
| Q4 2022 | $169 | -99.9% | 28,602 | +0.1% | 0.00% | – |
| Q3 2022 | $251,000 | +16.7% | 28,577 | +0.4% | 0.00% | – |
| Q2 2022 | $215,000 | -68.9% | 28,452 | -0.3% | 0.00% | -100.0% |
| Q1 2022 | $692,000 | -24.6% | 28,541 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $918,000 | -17.7% | 28,523 | +14.3% | 0.00% | 0.0% |
| Q3 2021 | $1,115,000 | -0.4% | 24,955 | -15.6% | 0.00% | 0.0% |
| Q2 2021 | $1,119,000 | +221.6% | 29,581 | +214.7% | 0.00% | – |
| Q1 2021 | $348,000 | +34.9% | 9,400 | +20.5% | 0.00% | – |
| Q4 2020 | $258,000 | – | 7,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |